<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recommendations from the American Society of Clinical Oncology for preventing and managing cardiac dysfunction in adult cancer survivors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recommendations from the American Society of Clinical Oncology for preventing and managing cardiac dysfunction in adult cancer survivors</h1>
<div class="graphic"><div class="figure"><div class="ttl">Recommendations from the American Society of Clinical Oncology for preventing and managing cardiac dysfunction in adult cancer survivors</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Guideline questions</td> </tr> <tr class="divider_bottom"> <td class="indent1">This clinical practice guideline addresses the following five overarching clinical questions: Which patients with cancer are at increased risk for developing cardiac dysfunction? Which preventative strategies minimize risk before initiation of therapy? What strategies minimize risk during potentially cardiotoxic therapy? What are the preferred surveillance and monitoring approaches during treatment in patients at risk for cardiac dysfunction? What are the preferred surveillance and monitoring approaches after treatment in patients at risk for cardiac dysfunction?</td> </tr> <tr> <td class="subtitle1_single">Target population</td> </tr> <tr class="divider_bottom"> <td class="indent1">The target population consists of adults with cancer for whom cardiotoxic anticancer therapies are being considered.</td> </tr> <tr> <td class="subtitle1_single">Target audience</td> </tr> <tr class="divider_bottom"> <td class="indent1">This clinical practice guideline is targeted to oncologists, cardiologists, primary care physicians, specialists, practice providers, and any other relevant member of a comprehensive multidisciplinary cancer care team, as well as patients and their caregivers.</td> </tr> <tr> <td class="subtitle1_single">Methods</td> </tr> <tr class="divider_bottom"> <td class="indent1">An expert panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature, with a focus on five overarching clinical questions.</td> </tr> <tr> <td class="subtitle1_single">1. Which patients with cancer are at increased risk for developing cardiac dysfunction?</td> </tr> <tr> <td class="indent1"><strong>Recommendation 1.1.</strong> It is recommended that patients with cancer who meet any of the following criteria should be considered at increased risk for developing cardiac dysfunction. <ul class="decimal_heading"> <li>Treatment that includes any of the following: <ul> <li>High-dose anthracycline (eg, doxorubicin ≥250 mg/m<sup>2</sup>, epirubicin ≥600 mg/m<sup>2</sup>) </li> <li>High-dose radiotherapy (RT; ≥30 Gy) where the heart is in the treatment field </li> <li>Lower-dose anthracycline (eg, doxorubicin &lt;250 mg/m<sup>2</sup>, epirubicin &lt;600 mg/m<sup>2</sup>) in combination with lower-dose RT (&lt;30 Gy) where the heart is in the treatment field </li> </ul> </li> <li>Treatment with lower-dose anthracycline (eg, doxorubicin &lt;250 mg/m<sup>2</sup>, epirubicin &lt;600 mg/m<sup>2</sup>) or trastuzumab alone, and presence of any of the following risk factors: <ul> <li>Multiple cardiovascular risk factors (≥2 risk factors), including smoking, hypertension, diabetes, dyslipidemia, and obesity, during or after completion of therapy </li> <li>Older age (≥60 years) at cancer treatment </li> <li>Compromised cardiac function (eg, borderline low left ventricular ejection fraction [50 to 55%], history of myocardial infarction, moderate or worse valvular heart disease) at any time before or during treatment </li> </ul> </li> <li>Treatment with lower-dose anthracycline (eg, doxorubicin &lt;250 mg/m<sup>2</sup>, epirubicin &lt;600 mg/m<sup>2</sup>) followed by trastuzumab (sequential therapy) </li> </ul> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.)</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Recommendation 1.2.</strong> No recommendation can be made on the risk of cardiac dysfunction in patients with cancer with any of the following treatment exposures: <ul class="decimal_heading"> <li>Lower-dose anthracycline (eg, doxorubicin &lt;250 mg/m<sup>2</sup>, epirubicin &lt;600 mg/m<sup>2</sup>) or trastuzumab alone and no additional risk factors (as defined in Recommendation 1.1) </li> <li>Lower-dose RT (&lt;30 Gy) where the heart is in the treatment field and no additional cardiotoxic therapeutic exposures or risk factors (as defined in Recommendation 1.1) </li> <li>Kinase inhibitors </li> </ul> (Evidence-based; evidence quality: low.)</td> </tr> <tr> <td class="subtitle1_single">2. Which preventative strategies minimize risk before initiation of therapy?</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 2.1.</strong> Avoid or minimize the use of potentially cardiotoxic therapies if established alternatives exist that would not compromise cancer-specific outcomes.</p> (Consensus-based; benefits outweigh harms; strength of recommendation: strong.)</td> </tr> <tr class="divider_bottom"> <td class="indent1"> <p><strong>Recommendation 2.2.</strong> Clinicians should perform a comprehensive assessment in patients with cancer that includes a history and physical examination, screening for cardiovascular disease risk factors (hypertension, diabetes, dyslipidemia, obesity, smoking), and an echocardiogram before initiation of potentially cardiotoxic therapies.</p> (Evidence- and consensus-based; benefits outweigh harms; evidence quality: high; strength of recommendation: strong.)</td> </tr> <tr> <td class="subtitle1_single">3. Which preventive strategies are effective in minimizing risk during the administration of potentially cardiotoxic cancer therapy?</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 3.1.</strong> Clinicians should screen for and actively manage modifiable cardiovascular risk factors (smoking, hypertension, diabetes, dyslipidemia, obesity) in all patients receiving potentially cardiotoxic treatments.</p> (Informal consensus and evidence-based; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: moderate.)</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 3.2.</strong> Clinicians may incorporate a number of strategies, including use of the cardioprotectant dexrazoxane, continuous infusion, or liposomal formulation of doxorubicin, for prevention of cardiotoxicity in patients planning to receive high-dose anthracyclines (eg, doxorubicin ≥250 mg/m<sup>2</sup>, epirubicin ≥600 mg/m<sup>2</sup>).</p> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.)</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Recommendation 3.3.</strong> For patients who require mediastinal RT that might impact cardiac function, clinicians should select lower radiation doses when clinically appropriate and use more precise or tailored radiation fields with exclusion of as much of the heart as possible. These goals can be accomplished through use of advanced techniques including the following: <ul class="decimal_heading"> <li>Deep-inspiration breath holding for patients with mediastinal tumors or breast cancer in which the heart might be exposed </li> <li>Intensity-modulated RT that varies the radiation energy while treatment is delivered to precisely contour the desired radiation distribution and avoid normal tissues </li> </ul> (Evidence-based and informal consensus; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: strong.)</td> </tr> <tr> <td class="subtitle1_single">4. What are the preferred surveillance and monitoring approaches during treatment in patients at risk for cardiac dysfunction?</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 4.1.</strong> Clinicians should complete a careful history and physical examination in patients who are receiving potentially cardiotoxic treatments.</p> (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: strong.)</td> </tr> <tr> <td class="indent1"><strong>Recommendation 4.2.</strong> In individuals with clinical signs or symptoms concerning for cardiac dysfunction during routine clinical assessment, the following strategy is recommended: <ul class="decimal_heading"> <li>Echocardiogram for diagnostic workup </li> </ul> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: strong.) <ul class="decimal_heading"> <li>Cardiac magnetic resonance imaging (MRI) or multigated acquisition (MUGA) scan if echocardiogram is not available or technically feasible (eg, poor image quality), with preference given to cardiac MRI </li> </ul> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.) <ul class="decimal_heading"> <li>Serum cardiac biomarkers (troponins, natriuretic peptides) or echocardiography-derived strain imaging in conjunction with routine diagnostic imaging </li> </ul> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.) <ul class="decimal_heading"> <li>Referral to a cardiologist based on findings </li> </ul> (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: strong.)</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 4.3.</strong> Routine surveillance imaging may be offered during treatment in asymptomatic patients considered to be at increased risk (Recommendation 1.1) of developing cardiac dysfunction. In these individuals, echocardiography is the surveillance imaging modality of choice that should be offered. Frequency of surveillance should be determined by health care providers based on clinical judgment and patient circumstances.</p> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.)</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 4.4.</strong> No recommendations can be made regarding continuation or discontinuation of cancer therapy in individuals with evidence of cardiac dysfunction. This decision, made by the oncologist, should be informed by close collaboration with a cardiologist, fully evaluating the clinical circumstances and considering the risks and benefits of continuation of therapy responsible for the cardiac dysfunction.</p> (Informal consensus; benefits outweigh harms; evidence quality: insufficient.)</td> </tr> <tr class="divider_bottom"> <td class="indent1"> <p><strong>Recommendation 4.5.</strong> Clinicians may use routine echocardiographic surveillance in patients with metastatic breast cancer continuing to receiving trastuzumab indefinitely. The frequency of cardiac imaging for each patient should be determined by health care providers based on clinical judgment and patient circumstances.</p> (Evidence-based and informal consensus; benefits outweigh harms; evidence quality: low; strength of recommendation: moderate.)</td> </tr> <tr> <td class="subtitle1_single">5. What are the preferred surveillance and monitoring approaches after treatment in patients at risk for cardiac dysfunction?</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 5.1.</strong> Clinicians should complete a careful history and physical examination in survivors of cancer previously treated with potentially cardiotoxic therapies.</p> (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: strong.)</td> </tr> <tr> <td class="indent1"><strong>Recommendation 5.1.1.</strong> In individuals with clinical signs or symptoms concerning for cardiac dysfunction, the following approaches should be offered as part of recommended care: <ul class="decimal_heading"> <li>Echocardiogram for diagnostic workup </li> </ul> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: strong.) <ul class="decimal_heading"> <li>Cardiac MRI or MUGA if echocardiogram is not available or technically feasible (eg, poor image quality), with preference given to cardiac MRI </li> </ul> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.) <ul class="decimal_heading"> <li>Serum cardiac biomarkers (troponins, natriuretic peptides) </li> </ul> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.) <ul class="decimal_heading"> <li>Referral to a cardiologist based on findings </li> </ul> (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: strong.)</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 5.2.</strong> An echocardiogram may be performed between 6 and 12 months after completion of cancer-directed therapy in asymptomatic patients considered to be at increased risk (Recommendation 1.1) of cardiac dysfunction.</p> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.)</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 5.2.1.</strong> Cardiac MRI or MUGA may be offered for surveillance in asymptomatic individuals if an echocardiogram is not available or technically feasible (eg, poor image quality), with preference given to cardiac MRI.</p> (Evidence-based; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.)</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 5.3.</strong> Patients identified to have asymptomatic cardiac dysfunction during routine surveillance should be referred to a cardiologist or a health care provider with cardio-oncology expertise for further assessment and management.</p> (Informal consensus; benefits outweigh harms; evidence quality: insufficient; strength of recommendation: strong.)</td> </tr> <tr> <td class="indent1"> <p><strong>Recommendation 5.4.</strong> No recommendations can be made regarding the frequency and duration of surveillance in patients at increased risk (Recommendation 1.1) who are asymptomatic and have no evidence of cardiac dysfunction on their 6- to 12-month post-treatment echocardiogram.</p> (Informal consensus; relative balance of benefits and harms; evidence quality: insufficient.)</td> </tr> <tr class="divider_bottom"> <td class="indent1"> <p><strong>Recommendation 5.5.</strong> Clinicians should regularly evaluate and manage cardiovascular risk factors such as smoking, hypertension, diabetes, dyslipidemia, and obesity in patients previously treated with cardiotoxic cancer therapies. A heart-healthy lifestyle, including the role of diet and exercise, should be discussed as part of long-term follow-up care.</p> (Evidence-based and consensus; benefits outweigh harms; evidence quality: intermediate; strength of recommendation: moderate.)</td> </tr> <tr> <td class="subtitle1_single">Additional resources</td> </tr> <tr class="divider_bottom"> <td class="indent1">More information, including a data supplement with additional evidence tables, a methodology supplement with information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at <a href="https://www.asco.org/practice-patients/guidelines/patient-and-survivor-care#/14726" target="_blank">www.asco.org/cardiac-guideline</a>. Patient information is available at <a href="https://www.cancer.net/" target="_blank">www.cancer.net</a>.</td> </tr> <tr> <td class="subtitle1_single">Qualifying statements</td> </tr> <tr> <td class="indent1"><strong>ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate.</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd">Recommendations for prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline.</div><div class="graphic_footnotes">RT: radiotherapy; MRI: magnetic resonance imaging; MUGA: multigated acquisition: ASCO: American Society of Clinical Oncology.</div><div class="graphic_reference">From: Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; Vol. 35(8):893-911. Reprinted with permission © 2017 American Society of Clinical Oncology.</div><div id="graphicVersion">Graphic 116340 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
